After getting hopes up, expectations on Gilead, Arcus' CD73 'dimmed' on new update
When you’ve got an alliance as hefty as the one Arcus and Gilead have, every update counts.
That’s why the companies found analysts frowning on the latest disclosure around quemliclustat, their small molecule inhibitor of CD73. Although an interim analysis from a triplet combo trial in pancreatic cancer looks “promising,” it didn’t seem that much different from chemotherapy alone — triggering a decision to wait for “more mature” progression-free survival and overall survival data before making a call.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.